ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System grew its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% during the fourth quarter, Holdings Channel reports. The firm owned 79,607 shares of the biotechnology company’s stock after acquiring an additional 897 shares during the quarter. Maryland State Retirement & Pension System’s holdings in ADMA Biologics were worth $1,365,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after purchasing an additional 80,400 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of ADMA Biologics in the third quarter valued at $61,858,000. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at $19,076,000. EWG Elevate Inc. acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at $480,000. Finally, Citigroup Inc. raised its stake in shares of ADMA Biologics by 251.7% in the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Stock Up 0.8 %

Shares of NASDAQ ADMA opened at $19.80 on Friday. The stock has a market cap of $4.68 billion, a P/E ratio of 70.71 and a beta of 0.60. The business’s fifty day simple moving average is $16.76 and its 200-day simple moving average is $18.04. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.